KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Debt: 2010-2025

Historic Non-Current Debt for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $663.1 million.

  • Emergent BioSolutions' Non-Current Debt rose 0.20% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 0.20%. This contributed to the annual value of $663.7 million for FY2024, which is 48.65% up from last year.
  • Emergent BioSolutions' Non-Current Debt amounted to $663.1 million in Q3 2025, which was down 0.70% from $667.8 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Debt peaked at $1.0 billion during Q3 2022, and registered a low of $446.5 million during Q4 2023.
  • Its 3-year average for Non-Current Debt is $546.0 million, with a median of $448.2 million in 2023.
  • In the last 5 years, Emergent BioSolutions' Non-Current Debt tumbled by 56.57% in 2023 and then skyrocketed by 49.40% in 2025.
  • Emergent BioSolutions' Non-Current Debt (MRQ) stood at $809.4 million in 2021, then tumbled by 44.59% to $448.5 million in 2022, then dropped by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then decreased by 0.09% to $663.1 million in 2025.
  • Its last three reported values are $663.1 million in Q3 2025, $667.8 million for Q2 2025, and $665.7 million during Q1 2025.